search
Back to results

Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools (RRMUT)

Primary Purpose

Developmental Disorders

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
genome-wide analyses
Search for de novo mutations in paternal sperm samples
Sponsored by
University Hospital, Rouen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Developmental Disorders

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Trio consisting of a child with a developmental disorder and both unaffected parents
  • Absence of etiology after clinical expertise and genetic testing
  • Indication of a genome-wide sequencing analysis
  • Child from spontaneous pregnancy without ovulation stimulation treatment
  • Availability of DNA blood samples
  • Affiliation to a social insurance
  • Patient or patient's legal representative who has read and understood the information letter and has signed the consent form

Exclusion Criteria:

  • Lack of indication for a genome-wide analysis in the proband
  • Etiology of the developmental disorder already identified
  • Proband born after In-Vitro Fertilization
  • Impossibility of non-invasive sperm collection from the father

Sites / Locations

  • Rouen University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Indication for a genome-wide analysis in the proband

Arm Description

Outcomes

Primary Outcome Measures

Proportion of the patient's de novo mutations detectable in the father's sperm

Secondary Outcome Measures

Number of patients for whom molecular diagnosis has been obtained (cause of developmental disability identified) ≥1

Full Information

First Posted
September 21, 2020
Last Updated
September 21, 2020
Sponsor
University Hospital, Rouen
search

1. Study Identification

Unique Protocol Identification Number
NCT04564235
Brief Title
Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools
Acronym
RRMUT
Official Title
Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 2020 (Anticipated)
Primary Completion Date
October 2022 (Anticipated)
Study Completion Date
October 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Inclusion of 5 families Inclusions will be made by the clinical genetics department of the Rouen University Hospital (monocentric study) and will correspond to trios of parents + child with unexplained developmental abnormalities. The inclusion of patients will be integrated in routine care and will have as immediate benefit for the included families the extensive analysis of the proband and their parents' genomes by short and long read sequencing techniques, which represent the most comprehensive diagnostic tests for developmental diseases, and which are not currently routinely available. Inclusion in clinical genetics by clinicians accustomed to prescribing genome-wide analyses will allow clear and complete information to families. Collection of consents. The trio's DNA will already be available at the molecular genetics laboratory, and a new blood sample may be proposed if necessary. Collection of sperm from the father. Identification of a large set of de novo mutations. Extraction of blood DNA and sending for sequencing of the complete genome to the National Centre for Research in Human Genomics (CNRGH, Evry), in the framework of a collaboration already initiated. Analysis of the sequencing data thanks to the already existing expertise in Rouen. Identification of about 40-120 de novo mutations per trio. At this stage: interpretation of the variations identified with the secondary objective of identifying the cause of the disease in children. Long read genomes will allow to phase the de novo variants to the paternal or to the maternal haplotype. Search for de novo mutations in paternal sperm samples. Extraction of spermatic DNA. Design of a sequencing panel targeting the genetic variations identified in the different trios. Preparation of the libraries, targeted high throughput sequencing at great depth thanks to the techniques and equipment already operational. Specific search for the de novo variations identified in the probands (in 2.), with for each evaluation of (i) the presence of the variation in the sperm sample, (ii) the quantity of mosaicism, reflecting the proportion of carrier spermatozoa and therefore the risk of recurrence, (iii) the presence of my variation in the blood sample of both parents in deep sequencing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Developmental Disorders

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Indication for a genome-wide analysis in the proband
Arm Type
Experimental
Intervention Type
Genetic
Intervention Name(s)
genome-wide analyses
Intervention Description
genome-wide analyses will be done in patients and parents (father, mother)
Intervention Type
Genetic
Intervention Name(s)
Search for de novo mutations in paternal sperm samples
Intervention Description
Sperm analysis will be done in paternal samples
Primary Outcome Measure Information:
Title
Proportion of the patient's de novo mutations detectable in the father's sperm
Time Frame
Day 1
Secondary Outcome Measure Information:
Title
Number of patients for whom molecular diagnosis has been obtained (cause of developmental disability identified) ≥1
Time Frame
Day 1

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Trio consisting of a child with a developmental disorder and both unaffected parents Absence of etiology after clinical expertise and genetic testing Indication of a genome-wide sequencing analysis Child from spontaneous pregnancy without ovulation stimulation treatment Availability of DNA blood samples Affiliation to a social insurance Patient or patient's legal representative who has read and understood the information letter and has signed the consent form Exclusion Criteria: Lack of indication for a genome-wide analysis in the proband Etiology of the developmental disorder already identified Proband born after In-Vitro Fertilization Impossibility of non-invasive sperm collection from the father
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
François LECOQUIERRE, MD
Phone
+3323288
Ext
8858
Email
francois.lecoquierre@chu-rouen.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Julien BLOT
Phone
+3323288
Email
julien.blot@chu-rouen.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
François LECOQUIERRE, MD
Organizational Affiliation
Rouen University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rouen University Hospital
City
Rouen
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François LECOQUIERRE, MD
First Name & Middle Initial & Last Name & Degree
Gael NICOLAS, MD
First Name & Middle Initial & Last Name & Degree
Nathalie RIVES, Pr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools

We'll reach out to this number within 24 hrs